Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

I Leader della Finanza

Ultime notizieSocietÓMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaAgendaSettori 
HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza
Portrait de Amy L. Schulman
EtÓ : 59
Patrimonio pubblico : 2 759 775 USD
Principali societÓ : Alnylam Pharmaceuticals, Inc. - SQZ Biotechnologies Company - Hudson Executive Investment Corp. II
Riassunto 
Founder of Lyndra Therapeutics, Inc. and Suono Bio, Inc., Amy L. Schulman is a businessperson who has been at the head of 7 different companies and currently holds the position of Chairman for SQZ Biotechnologies Co., Co-Executive Chairman at Lyndra Therapeutics, Inc. and Partner at Polaris Partners. Ms. Schulman is also Member of The Brookings Institution and on the board of 17 other companies.

Amy L. Schulman previously occupied the position of Executive Chairman for Suono Bio, Inc., President & General Manager at Nutrition, Inc., President-Vaccines, Oncology & Consumer Healthcare at Pfizer Inc. Executive Vice President & General Counsel for Wyeth Corp. and Executive Vice President & General Counsel at Pfizer Consumer Healthcare (both are subsidiaries of Pfizer Inc.), Executive Chairman & Chief Executive Officer at Olivo Laboratories LLC, Chief Executive Officer of Eagle Biologics, Inc., President for Pfizer Nutrition and Partner at Advokatfirma DLA Piper Sweden AB.

Ms. Schulman received an undergraduate degree from Wesleyan University and a graduate degree from Yale Law School.


Posti e reponsabilitÓ di Amy L. Schulman 
NomeTitolo Da
Alnylam Pharmaceuticals, Inc.
(Biotecnologia)
Independent Director 2014
SQZ Biotechnologies Company
(Biotecnologia)
Chairman 2015
Hudson Executive Investment Corp. II
(SocietÓ Holding)
Independent Director 2021
The Brookings Institution Member -
Pet Products, Inc. Director -
Wesleyan University Director -
The Mount Sinai Hospital Director -
Equal Justice Works Director -
Action Against Hunger-USA Director -
Fractyl Laboratories, Inc. Director -
Kallyope, Inc. Director -
Lyndra Therapeutics, Inc. Co-Executive Chairman 2019
Cardurion Pharmaceuticals LLC Director 2019
Thirty Madison, Inc. Director -
Glympse Bio, Inc. Director -
Dewpoint Therapeutics, Inc. Director -
ByHeart, Inc. Director -
Volastra Therapeutics, Inc. Director -
Amagma, Inc. Director -
Vico Therapeutics BV Director 2020
Polaris Partners Partner -


Participazioni di Amy L. Schulman 
NomeAzioni%Valorizzazione
SQZ Biotechnologies Company (SQZ)
(Biotecnologia)
190 6840,68%2 536 097 USD
Hudson Executive Investment Corp. II20 0000,31%198 000 USD
Cyclerion Therapeutics, Inc. (CYCN)
(Biotecnologia)
7 5080,017%25 677 USD
Alnylam Pharmaceuticals, Inc. (ALNY)
(Biotecnologia)
00,0000%0 USD


Amy L. Schulman: network personale 
Le notizie pi¨ lette 
22/09WILLIAM ACKMAN: Il fondo Pershing Square di Ackman sale mentre Universal sale al debutto in borsa
MR
15/09BRAD SMITH: Microsoft annuncia il riacquisto di azioni fino a 60 miliardi di dollari e aumenta il dividendo
MR
13/09MARTIN SORRELL: S4 Capital di Sorrell alza le prospettive di profitto al 40%
MR
14/09STEPHEN SCHERR: Goldman Sachs nomina Coleman come nuovo CFO, sostituendo Scherr
MR
22/09JOHN ELKANN: Stellantis, Torino è città chiave per produzione gruppo - Elkann
RE
20/09GIUSEPPE CASTAGNA: Banco Bpm, non ci sono presupposti per consolidamento - Castagna a Corriere
RE
15/09FRANCESCO GAETANO CALTAGIRONE: Generali, Caltagirone aumenta quota di ulteriore 0,11%, sale sopra 6%
RE
14:06PHILIPPE DONNET: Generali, comitato nomine propone a maggioranza lista Cda con Donnet Ceo - fonti
RE
13:24ELON MUSK: Auto, con nuovi impianti semiconduttori carenza chip avrà vita breve - Musk (Tesla)
RE
22/09LEONARDO DEL VECCHIO: Generali, Del Vecchio arrotonda quota al 5,1%, patto con Caltagirone al 12,5%
RE
Pi¨ notizie


© 2021 People and Ownership :   
Amy L. Schulman : connessioni